TY - JOUR
T1 - Management of cancer treatment-related diarrhea
T2 - Issues and therapeutic strategies
AU - Kornblau, Steven
AU - Benson, Al B.
AU - Catalano, Robert
AU - Champlin, Richard E.
AU - Engelking, Constance
AU - Field, Michael
AU - Ippoliti, Cindy
AU - Lazarus, Hillard M.
AU - Mitchell, Edith
AU - Rubin, Joseph
AU - Stiff, Patrick J.
AU - Vokes, Everett
AU - Wadler, Scott
N1 - Funding Information:
This study was supported by an educational grant from Novartis Pharmaceuticals Corporation.
PY - 2000
Y1 - 2000
N2 - The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.
AB - The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.
KW - Bone marrow transplant
KW - Diarrhea
KW - Fluoropyrimidines
KW - Graft-versus-host disease
KW - Irinotecan
KW - Octreotide
UR - http://www.scopus.com/inward/record.url?scp=0034000694&partnerID=8YFLogxK
U2 - 10.1016/S0885-3924(99)00149-9
DO - 10.1016/S0885-3924(99)00149-9
M3 - Article
C2 - 10699539
AN - SCOPUS:0034000694
SN - 0885-3924
VL - 19
SP - 118
EP - 129
JO - Journal of Pain and Symptom Management
JF - Journal of Pain and Symptom Management
IS - 2
ER -